Inclisiran Sodium

CAS 2563732-45-7 3 FDA-DMF suppliersNucleotide

Overview

Inclisiran Sodium is a small interfering RNA (siRNA) therapeutic that targets and degrades the mRNA of PCSK9, a protein involved in cholesterol metabolism. It is designed to reduce low-density lipoprotein cholesterol (LDL-C) levels and is used primarily for the treatment of hyperlipidemia.

Therapeutic areas

CardiovascularLipid Metabolism

Related APIs

Cholestyramine
4 suppliers
Rivaroxaban
57 suppliers
Apixaban
51 suppliers
Telmisartan
43 suppliers
Empagliflozin
42 suppliers
Clopidogrel
40 suppliers
Olmesartan Medoxomil
38 suppliers
Valsartan
37 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo